Physician profile
Lauren Thomas
NPI 1104387463
$1,589.18
in general payments reported to CMS, 2019-2025
18 companies · $696 in 2025
The $696 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.07 · 2023: $84.17 · 2024: $713 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $377.58 | 2023-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $192.56 | 2023-2024 | |
| Exeltis, USA INC. | $179.44 | 2024-2025 | Slynd, Twirla |
| Baxter Healthcare | $152.17 | 2021-2025 | Perclot |
| Astellas Pharma US INC | $104.73 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $98.86 | 2023-2025 | Myfembree, Gemtesa |
| Novo Nordisk INC | $95.04 | 2024-2025 | Wegovy |
| Millicent US INC | $81.07 | 2024-2025 | Intrarosa |
| Daiichi Sankyo INC. | $50.79 | 2024 | Injectafer |
| Pfizer INC. | $48.09 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.82 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $37.84 | 2025 | Qelbree |
| Hologic Sales and Service, LLC | $29.79 | 2024-2025 | Myosure Tissue Removal Device, Novasure |
| Merck Sharp & Dohme LLC | $29.06 | 2023-2024 | Gardasil 9, Gardasil |
| Shield Therapeutics INC | $19.93 | 2023 | Accrufer |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $18.93 | 2025 | Venaseal |
| Abbvie INC. | $18.05 | 2024 | |
| Organon LLC | $16.43 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.